Pioglitazone may reduce body fat inflammation in insulin resistance
Key takeaway:
In insulin-resistant adults with impaired glucose tolerance, pioglitazone was linked to fewer inflammatory cells in adipose tissue, better capillary density, higher elastin content, and improved insulin sensitivity.
Study at a glance
What was studied
Pioglitazone effects on adipose inflammation and vascularity in insulin-resistant adults with impaired glucose tolerance
Study type
non-randomized clinical trial (non-RCT or NRCT)
duration
Medium-Term (3–12 mo)
Intervention
Pioglitazone
Outcomes
Insulin sensitivity, Adipose tissue macrophage count, Adipose tissue mast cell count, Capillary density, Adipose tissue elastin content
Funding
Non-industry sponsored
Main effects
Adipose tissue macrophage count ↓ after pioglitazone
Adipose tissue mast cell count ↓ after pioglitazone
Capillary density ↑ and elastin content ↑ in adipose tissue
Insulin sensitivity ↑ after treatment
Evidence Summary
| Intervention | Outcome | Measured Change | Study Effect |
|---|---|---|---|
 Pioglitazone (Medications) |  Adipose tissue elastin content (Metabolic Health) | Increase | Strong |
Pioglitazone (Medications) | Adipose tissue macrophage count (Metabolic Health) | Decrease | Strong |
Pioglitazone (Medications) | Adipose tissue mast cell count (Metabolic Health) | Decrease | Strong |
Pioglitazone (Medications) | Capillary density (Metabolic Health) | Increase | Strong |
Pioglitazone (Medications) | Insulin sensitivity (Metabolic Health) | Increase | Strong |
Unlock Full Evidence Analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Pioglitazone lowered total adipose macrophages and reduced pro-inflammatory M1 macrophages.
- Mast cell density fell from 24 to 13 cells per mm2 after pioglitazone treatment.
- Capillary density and adipose elastin content increased, suggesting improved tissue structure and blood supply.
- Insulin sensitivity improved in the treated participants in the paired pre-post analysis.
Who this applies to
These findings apply most directly to obese, insulin-resistant adults with impaired glucose tolerance who are at high risk for type 2 diabetes. The results are especially relevant to people being studied for early metabolic dysfunction rather than established treated diabetes.
Keep in Mind
The improvements were seen mainly in adipose tissue biology and insulin sensitivity, not in a large clinical outcomes trial. The treatment group was small, and this paper re-used participants from previous intervention studies. That means the study helps explain how pioglitazone may work, but it does not by itself prove broad clinical benefit for all high-risk patients.
Between the Lines
- Only nine participants were included in the pioglitazone tissue analysis.
- This was a secondary mechanistic analysis based on prior intervention cohorts.
- There was no dedicated parallel placebo group for the pioglitazone biopsy analysis.
- Most outcomes were tissue and biomarker measures rather than patient-centered clinical outcomes.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Journal Reference
Spencer M, Yang L, Adu A, et al. Pioglitazone Treatment Reduces Adipose Tissue Inflammation through Reduction of Mast Cell and Macrophage Number and by Improving Vascularity. PLoS One. 2014;9(7):e102190. doi:10.1371/journal.pone.0102190
Sources
Ranked by clinical relevance and evidence quality.
Key References
Most relevant evidence and guidance related to this research.
Prevention or delay of diabetes and associated comorbidities: Standards of Care in Diabetes 2025
CDC: Prediabetes - Your Chance to Prevent Type 2 Diabetes
Supporting Evidence
Supporting evidence and related resources.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.